Download PDF
Thromb Haemost 1980; 43(01): 025-027
DOI: 10.1055/s-0038-1650004
Original Article
Schattauer GmbH Stuttgart

In vivo Characteristics of Thaw Siphon Cryoprecipitate Compared to Other Factor VIII Preparations

F Toolis
The Department of Haematology and South-East Scotland, Regional Blood Transfusion Service, Royal Infirmary, Edinburgh
,
G McKay
The Department of Haematology and South-East Scotland, Regional Blood Transfusion Service, Royal Infirmary, Edinburgh
,
C V Prowse
The Department of Haematology and South-East Scotland, Regional Blood Transfusion Service, Royal Infirmary, Edinburgh
› Author Affiliations
Further Information

Publication History

Received 10 September 1979

Accepted 26 October 1979

Publication Date:
13 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

5 severe haemophiliacs were infused with cryoprecipitate prepared by the continuous thaw-siphon technique, with cryoprecipitate prepared by overnight thawing and with intermediate-purity factor VIII concentrate. All 3 preparations gave a similar mean half-life for coagulant factor VIII of approximately 10 hours. The immediate recovery of this activity was similar for the 2 cryoprecipitates, but higher for the purified concentrate.

Keywords

Cryoprecipitate - Factor VIII concentrate - Haemophilia
 

  • References

  • 1 Nilsson IM, Hedner U. Characteristics of various factor VIII concentrates used in treatment of Haemophilia A. Br J Haematol 1977; 37: 543-557
    CrossrefPubMedGoogle Scholar
  • 2 Smith JK, Bidwell E. Therapeutic materials used in the treatment of coagulation defects. Clin Haematol 1979; 8: 183-206
    PubMedGoogle Scholar
  • 3 Pool JG, Shannon AE. Production of high potency concentrates of anti-haemophilic globulin in a closed bag system; assay in vitro and in vivo. N Engl J Med 1965; 273: 1443-1447
    CrossrefPubMedGoogle Scholar
  • 4 Johnson AJ, Karpatkin MH, Newman J. Preparation and clinical experience with anti-haemophilic factor concentrate. Thromb Diath Haemorrh 1969; suppl 35: 49
    PubMedGoogle Scholar
  • 5 Mason EC. Thaw-siphon technique for production of cryoprecipitate concentrate for factor VIII. Lancet 1978; ii: 15-17
    PubMedGoogle Scholar
  • 6 Prowse CV, McGill A. Evaluation of the "Mason" (continuous-thawsiphon) method for cryoprecipitate production. Vox Sang 1979; 37: 235-243
    PubMedGoogle Scholar
  • 7 Prowse CV, Sas G, Gader AM A, Cort JH, Cash JD. Specificity in the factor VIII response to vasopressin infusion in man. Br J Haematol 1979; 41: 437-447
    CrossrefPubMedGoogle Scholar
  • 8 McFarlane EE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308
    PubMedGoogle Scholar
  • 9 Ellis BC, Stransky A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 1961; 58: 477-488
    PubMedGoogle Scholar
  • 10 Hardisty RM, Ingram GI C. Bleeding disorders: Investigation and management. Blackwell Scientific Publications Ltd., Oxford. 1965
    Google Scholar
  • 11 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Ark Kemi 1956; 10: 415-426
    PubMedGoogle Scholar
  • 12 Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Anti-haemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding time factor and ristocetin-cofactor activities. JAMA 1976; 236: 2770-2772
    CrossrefPubMedGoogle Scholar
  • 13 Allain JP, Verroust F, Soulier JP. 1 or 2-stage assay for factor VIII. Lancet. 1979; i: 1076-1077
    PubMedGoogle Scholar
  • 14 Kirkwood TB L, Barrowcliffe TW. Discrepancy between 1-stage and 2-stage assays of factor VIII:C. Br J Haematol 1978; 40: 333-338
    CrossrefPubMedGoogle Scholar
  • 15 Mason EC, Harden PA, Shaw AE. The thaw-siphon procedure for cryoprecipitate production: an alternative pathway to an improved intermediate AHF concentrate within a closed pack system. Joint Congress of the International Society of Haematology and the International Society of Blood Transfusion, Paris 1978 Abstracts 1: p. 603
    PubMedGoogle Scholar